AVAV · Desk conversation

Start with the day, not the tickers. The sealed proxy has 208 decliners against 91 advancers across 300 fresh quotes. Oil, producer prices and yields make this a demanding environment for continuation, although breadth is context rather than a ranking formula.

Then the policy question is prospective: which company mechanism can remain useful through fifteen sessions? A large print, an internal score or a good story cannot substitute for mechanism, participation, relative behavior and a falsifiable path.

AVAV has heavy participation and held most of its reaction across five observations, but the larger frames still lean down. I see a forceful repair, not an established trend. CMRC has the cleaner near-term chart sequence, though its last move is abrupt.

AVAV also has the best practical capacity in the retained set: roughly $802 million of observed dollar volume and broad options coverage. That helps observability, not safety. The weak twenty-session structure and acquisition-era balance-sheet risks still matter.

The issuer-linked filing and explicit episode identity make AVAV auditable. CULP has even cleaner current-lineage simplicity, but lineage alone does not make its fade below VWAP a continuation thesis.

My narrower preference is MDA. Its primary announcement and restrained path are easier to describe without exaggeration. The problem is equally plain: 0.39 times average volume and no booking, revenue or guidance conversion.

That is why AVAV leads for me. MDA has a product announcement; AVAV has a broader defense-demand mechanism supported by a filing, quarterly operating evidence and visible participation. The next question is conversion, not whether anyone noticed.

CMRC should remain visible as the tape alternative. Higher lows and volume-backed recovery are real observations. But its extended finish and weaker primary bridge make it harder to defend if the move reverses.

CULP's 26.3-times volume looks like churn once price falls below VWAP. TSSI held its coarse trajectory better, but we lack intraday location and cannot reconcile the positive reported quarter with the older SEC period.

The specialist rankings are not independent ballots. They are five typed readings of the same selected artifact: Marcus chose AVAV, Elena and Priya chose MDA, Nate chose CMRC, and I chose CULP on lineage. Those disagreements define the checks; they do not add votes.

The model does not resolve the dispute. AVAV's H15 probability is about 50.40%, while the model adverse P10 is about -27.69% and the historical adverse comparison contains eight cases. That is uncertainty context, not selection authority.

AVAV currently clears Try of the Day because the mechanism, primary-event provenance, liquidity and retained reaction coexist. MDA is cleaner but economically unconfirmed; CMRC is technically cleaner but less well anchored. The decision fails if AVAV loses its supplied structure or the operating mechanism does not convert.

Reopen: {'speaker_id': 'guest_publication_auditor', 'text': 'The AVAV thesis remains plausible, but the public record needs reconsideration. MDA is described from a source the dossier does not clear for public citation, and the draft exposes internal preference rankings in a vote-like way. The model also does not independently favor AVAV over MDA: the H15 estimates are 50.40% versus 53.70%, with a less adverse MDA distribution. Finally, the stated 2.73% VWAP cushion is not aligned with the latest tape, which is closer to 0.90%. Please revisit this same decision and its public framing without turning the model into a selector.'}

Agreed. The MDA row now uses only sealed observed prices, VWAP, volume and relative performance. The uncleared narrative source is removed, and the row says plainly that commercial impact is unconfirmed.

The earlier ranking language exposed the scaffolding of the review. The reports were derived from one sealed artifact and applied different lenses; the corrected record preserves that disagreement as advisory provenance, not as a ballot.

The VWAP arithmetic also changes. With ordered prices around 154.50 to 154.55 and a 153.21 reference, the immediate difference is approximately 0.8 to 0.9 percent. Because the captures are not synchronous, the public wording stays approximate.

That narrower cushion matters for the first checkpoint. It does not erase AVAV’s participation, but it makes the 153.21 level a tighter test and keeps 145.76 as the supplied downside reference.

MDA’s model context must be visible as a counterweight: 53.7 percent versus AVAV’s 50.4 percent, with the less adverse sealed H15 quantile. That is context, not a machine verdict, and it cannot replace the missing publicly available commercial proof.

Both model comparisons come from eight comparable cases, and the SEC-aware inputs are contextual rather than point-in-time validated. The public record now presents probability and adverse tail together instead of using one side asymmetrically.

The hash differences, chart omission for TSSI and provider-label mismatches remain representation or coverage warnings. They do not change the panel case, AVAV episode or review data, so they do not trigger another Desk.

The alternatives remain visible as evidence-led rows. CMRC’s recovery structure, CULP’s fading post-earnings move and TSSI’s unreconciled pivot are described without assigning ballot positions.

After these repairs, AVAV still holds the same Try of the Day. The thesis is narrower at the margin: the market response and dated program conversion must survive the next checks.